WO2001008697A3 - Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof - Google Patents

Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof Download PDF

Info

Publication number
WO2001008697A3
WO2001008697A3 PCT/US2000/020668 US0020668W WO0108697A3 WO 2001008697 A3 WO2001008697 A3 WO 2001008697A3 US 0020668 W US0020668 W US 0020668W WO 0108697 A3 WO0108697 A3 WO 0108697A3
Authority
WO
WIPO (PCT)
Prior art keywords
stanniocalcin
type
diabetes
treatment
human
Prior art date
Application number
PCT/US2000/020668
Other languages
French (fr)
Other versions
WO2001008697A2 (en
Inventor
Emma E Moore
Gary Rosenberg
Angela Thostrud
David S Weigle
Hong Ping Ren
Original Assignee
Zymogenetics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc
Priority to AU66131/00A priority Critical patent/AU6613100A/en
Publication of WO2001008697A2 publication Critical patent/WO2001008697A2/en
Publication of WO2001008697A3 publication Critical patent/WO2001008697A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides a definitive localization of human stanniocalcin 2 mRNA to the pancreas and further localizes stanniocalcin 2 protein synthesis to the pancreatic alpha cells. Also, the present invention demonstrates a correlation between an increase in plasma stanniocalcin 2 and plasma insulin which is lost in individuals suffering from type II diabetes mellitus. These data demonstrate that therapeutic and prophylactic amounts of a composition comprising human stanniocalcin 2 and biologically functional derivatives and fragments thereof are useful in the modulation of glucose homeostasis. In particular, methods for the use of human stanniocalcin 2 in the diagnosis and treatment of type II diabetes and chronic conditions associated therewith are provided.
PCT/US2000/020668 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof WO2001008697A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66131/00A AU6613100A (en) 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14659999P 1999-07-30 1999-07-30
US60/146,599 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001008697A2 WO2001008697A2 (en) 2001-02-08
WO2001008697A3 true WO2001008697A3 (en) 2001-06-14

Family

ID=22518123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020668 WO2001008697A2 (en) 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof

Country Status (2)

Country Link
AU (1) AU6613100A (en)
WO (1) WO2001008697A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093864A2 (en) * 2008-01-25 2009-07-30 Regeron, Inc. Composition for preventing or treating brain diseases
GB0802009D0 (en) * 2008-02-04 2008-03-12 Chroma Therapeutics Ltd Biomarkers of aminopeptidase inhibition
US20180236035A1 (en) * 2010-05-03 2018-08-23 Scott & White Healthcare Protein therapy for treatment of retinal diseases
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670377A (en) * 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670377A (en) * 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOORE E E ET AL: "Stanniocalcin 2: Characterization of the protein and its localization to human pancreatic alpha cells.", HORMONE AND METABOLIC RESEARCH, vol. 31, no. 7, July 1999 (1999-07-01), pages 406 - 414, XP000979515 *

Also Published As

Publication number Publication date
AU6613100A (en) 2001-02-19
WO2001008697A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
WO1997002004A3 (en) Methods for treating diabetes
EP1409006A4 (en) Methods of treating diabetes mellitus
HUP0102193A2 (en) Glucagon-like peptide-1 improves betha-cell response to glucose in subjects with impaired glucose tolerance
WO2007113648A3 (en) Ctla4 antibody combination therapy
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2004012721A3 (en) Hot melt tts for administering rotigotine
MXPA03006771A (en) Modified antibodies and methods of use.
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
AU2003201274A1 (en) Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
WO1999050268A3 (en) Substituted indolealkanoic acids
WO2006013209A3 (en) Compounds for inhibiting copper-containing amine oxidases and uses thereof
WO2003025121A3 (en) Igf-binding protein-derived peptide or small molecule
EP0797999A3 (en) Formulations of obesity protein
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2000074710A3 (en) Methods for treating diabetes
WO2004083236A3 (en) Cancer treatment using proanp peptides
WO2001000566A3 (en) Substituted phenoxyacetic acids
WO2001008697A3 (en) Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2003099318A3 (en) Pancreas-specific proteins
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP